Phaseline

Targets › TRPM8

TRPM8 (Transient receptor potential cation channel subfamily M member 8): drug programs, companies and trials

4 programs from 4 companies in 7 trials: 3 Phase 3, 2 Phase 2, 2 Phase 4; Neurology, Respiratory, Immunology; next expected readout Dec 2026.

Non-selective ion channel permeable to monovalent and divalent cations, including Na(+), K(+), and Ca(2+), with higher permeability for Ca(2+). Activated by multiple factors, such as temperature, voltage, pressure, and changes in osmolality. (UniProt, Q7Z2W7)

Open in Phaseline: the race on TRPM8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Center For SightTRYPTYR (Acoltremon ophthalmic solution 0.003%)
TRPM8 channel agonist
TRPM8Phase 4Sjogren Syndrome With KeratoconjunctivitisDec 2026
Sport and Spine Rehab Clinical Research FoundationMenthol
Transient receptor potential cation channel subfamily M member 8 opener; Transient receptor potential cation channel subfamily A member 1 opener
TRPM8, TRPA1Phase 4Chronic Low Back Pain–
TriGemX BioElismetrep (K-304)
Transient receptor potential cation channel subfamily M member 8 inhibitor
TRPM8Phase 3Migraine; Acute MigraineFeb 2027
Region SkaneMenthol
Transient receptor potential cation channel subfamily M member 8 opener; Transient receptor potential cation channel subfamily A member 1 opener
TRPM8, TRPA1Phase 2Interstitial Lung Disease (ILD); AsthmaFeb 2027

Conditions

Migraine (2) Acute Migraine (1) Interstitial Lung Disease (ILD) (1) Asthma (1) Sjogren Syndrome With Keratoconjunctivitis (1) Chronic Low Back Pain (1)

Modalities

small molecule (4)

Companies

TriGemX Bio (1) Region Skane (1) Center For Sight (1) Sport and Spine Rehab Clinical Research Foundation (1)

Related targets

TRPA1 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.